Advacan（Everolimus 0.25mg)

Advacan is also known as Indian Generic AFINITOR (Everolimus), is a kinase inhibitor indicated for the treatment of:

1. Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
2. Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors.
3. Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
4. Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.

Everolimus are kinase inhibitors indicated for the treatment of:

5. Pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.

ADVERSE REACTIONS：

Advanced HR+ BC, advanced NET, advanced RCC: Most common adverse reactions (incidence ≥30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.

Renal angiomyolipoma with TSC: Most common adverse reaction (incidence ≥ 30%) is stomatitis. SEGA with TSC: Most common adverse reactions (incidence ≥30%) are stomatitis and respiratory tract infection.

Advacan’s brand name in US is AFINITOR by Novartis. Advacan is a generic prescription medicine from Biocon, which is one of the biggest pharmaceutical company in India.

For more Prescribing information，please check the → “FDA Prescribing Information”.